Metabolomic Approaches in NASH and NAFLD R&D

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. It encompasses a spectrum of diseases that range from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Over the next decade, health experts expect NASH to become the leading cause of liver transplants.

Currently, there are no FDA-approved treatments for NASH. A diverse set of disease drivers including genetics, environmental cues, microbiota metabolism and lifestyle influences come together resulting in an uncertain natural history of NAFLD/NASH. The constellation of risk factors for NASH has spawned a remarkable array of targets, and there is a significant need to bring the most effective treatments through development and to patients quickly.

This webinar reviews applications of metabolomics in NASH research, including a recent study designed and carried out by Dr. Jamie Bates of Gilead Sciences. It also highlights new tools Metabolon currently offers NAFLD/NASH liver disease researchers.

    Metabolomic Approaches in NASH and NAFLD R&D

    Contact Us

    Talk with an expert

    Request a quote for our services or more information on sample types and handling procedures, need a letter of support, or simply have questions about how metabolomics can advance your research.

    Corporate Headquarters

    617 Davis Drive, Suite 100
    Morrisville, NC 27560

    Mailing Address:
    P.O. Box 110407
    Research Triangle Park, NC 27709

    +1 (919) 572-1711

    +1 (919) 572-1721

    International Headquarters

    Metabolon GmbH

    Zeppelinstraße 3
    85399 Hallbergmoos

    +49 89 99017752